Advances in mesenchymal stem cell therapy for lupus nephritis

Area of Science:

• Immunology
• Nephrology
• Regenerative Medicine

Background:

• Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus, often leading to end-stage renal disease and mortality.
• Current treatments for LN include glucocorticoids, immunosuppressants, and biologics, but novel therapies are needed.

Purpose of the Study:

• To review the potential of mesenchymal stem cells (MSCs) as a therapeutic strategy for lupus nephritis.
• To summarize MSC sources, immunomodulatory mechanisms, and clinical trial outcomes in LN.

Main Methods:

• Literature review of preclinical and clinical studies on MSC therapy for LN.
• Analysis of MSC mechanisms, including immune suppression and renal function restoration.
• Examination of clinical trial data on MSC efficacy, safety, and limitations.

Main Results:

• MSCs demonstrate immunomodulatory effects, suppressing autoimmunity and reducing inflammation in LN.
• Clinical trials show promising but inconsistent outcomes regarding proteinuria alleviation and renal function recovery.
• MSC therapy presents potential benefits but requires further investigation into safety and efficacy.

Conclusions:

• Mesenchymal stem cells hold significant therapeutic potential for lupus nephritis.
• Further large-scale randomized controlled trials are essential to validate MSC efficacy and safety.
• Future research should focus on personalized and combinatorial approaches for MSC-based LN treatment.